INFUSIONAL CYCLOPHOSPHAMIDE (C), DOXORUBICIN (D), AND ETOPOSIDE (E): AN ACTIVE REGIMEN IN RELAPSED (RL) NON-HODGKIN'S LYMPHOMA (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


INFUSIONAL CYCLOPHOSPHAMIDE (C), DOXORUBICIN (D), AND ETOPOSIDE (E): AN ACTIVE REGIMEN IN RELAPSED (RL) NON-HODGKIN'S LYMPHOMA (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A1001 1991. Unique Identifier : AIDSLINE ICDB/91672363
Sparano JA; Wiernik PH; Trager M; Dutcher JP; Albert Einstein Cancer Center, Bronx, NY

Abstract: 31 patients (pts) with RL (prior complete response [CR]), refractory (RF--no prior CR or resistant relapse) or transformed (T-prior low grade NHL) intermediate (25 pts) or high-grade (6 pts) NHL not eligible for other trials were treated (Rx) with CDE given as a continuous iv infusion over 4 days at two dose levels (DL): DL-I--C 750, D 50, E 240 mg/m2; DL-II--C 1000, D 60 , E 400 mg/m2. Pt characteristics: RL-10, RF-14, T-7; median age 48 (22-81); sex M-16, F-15; median number prior Rx-1 (1-5); extranodal sites-22; + marrow-15; T-cell-8; HIV+-1; HTLV-I+-2. All RL/RF pts except one had received D previously. Results are presented in a table. No difference in toxicity existed between those with or without marrow involvement, or between those Rx at DL-I or DL-II. The mean dose of D administered prior to CDE was 223 mg/m2 (range 0-490). One pt developed atrial fibrillation, but no other cardiac toxicity developed. Conclusion: Infusional CDE is an active regimen in pts with RL NHL. This is analogous to myeloma, where infusional Rx (VAD) is active in RL pts, and confirms the importance of drug schedule in the Rx of lymphoid tumors.
Keywords: Adult Aged Aged, 80 and over Antineoplastic Agents, Combined/THERAPEUTIC USE Cyclophosphamide/*THERAPEUTIC USE Doxorubicin/*THERAPEUTIC USE Etoposide/*THERAPEUTIC USE Female Human Infusions, Intravenous Lymphoma, Non-Hodgkin's/*DRUG THERAPY/MORTALITY Male Middle Age Neoplasm Recurrence, Local/*DRUG THERAPY/MORTALITY Prognosis Survival Rate ABSTRACTKWDadultagedaged,80andoverantineoplasticagents,combined/therapeuticusecyclophosphamide/KWDtherapeuticusedoxorubicin/KWDtherapeuticuseetoposide/KWDtherapeuticusefemalehumaninfusions,intravenouslymphoma,non-hodgkin's/KWDdrugtherapy/mortalitymalemiddleageneoplasmrecurrence,local/KWDdrugtherapy/mortalityprognosissurvivalrateabstract
911030
M91A1124

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .